Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Allogeneic transplantation for multiple myeloma: yes, no or maybe?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G et al. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant (e-pub ahead of print 21 December 2015; doi:10.1038/bmt.2015.319).

  2. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantationfor multiple myeloma. N Engl J Med 2012; 366: 1770–1781.

    Article  CAS  Google Scholar 

  3. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.

    Article  CAS  Google Scholar 

  4. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.

    Article  Google Scholar 

  5. Bruno B, Rotta M, Patriarca F, Rotta M, Sorasio R, Allione B et al. A comparison of allografting with autografting for newly-diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120.

    Article  CAS  Google Scholar 

  6. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914–3915.

    Article  CAS  Google Scholar 

  7. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F et al. Non- myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375–3382.

    Article  CAS  Google Scholar 

  8. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383–3391.

    Article  CAS  Google Scholar 

  9. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721–6727.

    Article  CAS  Google Scholar 

  10. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al. Tandem autologous versus single autologous transplantation followed by allogeneic hematopoietic cell transplantation for patients with multiple myeloma: results from the blood and marrow transplant clinical trials network (BMT CTN) 0102 trial. Lancet Oncol 2011; 12: 1195–2003.

    Article  Google Scholar 

  11. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L et al. Tandemautologous/reduced-intensity conditioning allogeneic stem-cell transplanttation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016–3022.

    Article  Google Scholar 

  12. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity conditioning allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055–5063.

    Article  CAS  Google Scholar 

  13. Armeson KE, Hill EG, Costa LJ . Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013; 48: 562–567.

    Article  CAS  Google Scholar 

  14. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863–2869.

    Article  CAS  Google Scholar 

  15. Festuccia M, Martino M, Ferrando F, Messica G, Moscato T, Fedele R et al. Allogeneic stemcell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opin Biol Ther 2015; 15: 857–872.

    Article  CAS  Google Scholar 

  16. Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 398–404.

    Article  Google Scholar 

  17. Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia 2015; 29: 689–695.

    Article  CAS  Google Scholar 

  18. Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N et al. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia (e-pub ahead of print 6 October 2015; doi:10.1038/leu.2015.269).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B Bruno.

Ethics declarations

Competing interests

The author declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bruno, B. Allogeneic transplantation for multiple myeloma: yes, no or maybe?. Bone Marrow Transplant 51, 506–507 (2016). https://doi.org/10.1038/bmt.2016.12

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.12

Search

Quick links